1. Coronary Artery Calcium: Utilization for Primary Prevention of CHD

   • Harvey S. Hecht

   Editorial 03 September 2011 Pages: 465 - 474

   

2. The ACCOMPLISH Trial: Will First-Line Hypertension Therapy Change?

   • Matthew J. Sorrentino

   Clinical Trial Report 06 August 2011 Pages: 475 - 477

3. Can Catheter-Based Renal Denervation Be Used Safely and Effectively to Substantially Reduce Blood Pressure in Treatment-Resistant Hypertensive Patients?

   • Suzanne Oparil

   Clinical Trial Report 16 August 2011 Pages: 478 - 480

4. Stuck between Goal Achievement and Evidence-based Medicine

   • Michael H. Davidson

   Clinical Trial Report 26 August 2011 Pages: 481 - 484

5. What Is the Blood Pressure Goal for the Elder Patient 75 Years of Age or Older?

   • Gary E. Sander
   • Thomas D. Giles

   Hypertension (Matthew Sorrentino, Section Editor) 05 October 2011 Pages: 485 - 491

6. What is the Ideal Blood Pressure Goal for Patients with Stage III or Higher Chronic Kidney Disease?

   • Yazan Khouri
   • Susan P. Steigerwalt
   • Peter A. McCullough

   Hypertension (Matthew Sorrentino, Section Editor) 02 September 2011 Pages: 492 - 501

   

7. Is There a Role for Measuring Central Aortic Pressure?

   • Yonghong Huan
   • Raymond Townsend

   Hypertension (Matthew Sorrentino, Section Editor) 25 August 2011 Pages: 502 - 506

   

8. Should β Blockers No Longer Be Considered First-line Therapy for the Treatment of Essential Hypertension Without Comorbidities?

   • William J. Elliott
   • W. Kurtis Childers

   Hypertension (Matthew Sorrentino, Section Editor) 07 September 2011 Pages: 507 - 516

   

9. Can Treating the Diastolic Blood Pressure Below a Certain Value Increase Cardiovascular Risk?

   • Norman M. Kaplan

   Hypertension (Matthew Sorrentino, Section Editor) 16 August 2011 Pages: 517 - 519

10. What is the Role of Aldosterone Excess in Resistant Hypertension and How Should It Be Investigated and Treated?

    • Domenic A. Sica

    Hypertension (Matthew Sorrentino, Section Editor) 13 October 2011 Pages: 520 - 526

    

11. Familial Hypercholesterolemia: Present and Future Management

    • B. Sjouke
    • D. M. Kusters
    • G. K. Hovingh

    Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor) Open access 21 September 2011 Pages: 527 - 536

12. Apo A-I Modulating Therapies

    • Stephen J. Nicholls

    Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor) 24 September 2011 Pages: 537 - 543

13. The Role of Triglycerides in Atherosclerosis

    • Beatriz G. Talayero
    • Frank M. Sacks

    Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor) 04 October 2011 Pages: 544 - 552

14. Predictors of Statin Adherence

    • Alexander Mauskop
    • William B. Borden

    Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor) 27 September 2011 Pages: 553 - 558

15. CETP Inhibition: Does the Future Look Promising?

    • Peter P. Toth

    Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor) 10 September 2011 Pages: 559 - 565